Editors’ Picks: November Highlights from the AACR Journals
As the deep reds and yellows of fall leaves give way to twinkling holiday lights, we welcome the new...
As the deep reds and yellows of fall leaves give way to twinkling holiday lights, we welcome the new...
When teacher Ellen Reich began treatment for multiple myeloma in 2014, a sequence of therapies approved by the U.S....
The word myeloma stems from the Greek word “myelos,” for marrow. Indeed, this type of blood cancer begins in the plasma cells, a type...
Multiple myeloma is a cancer of antibody-producing cells—called plasma cells—that accounts for approximately 1.8 percent of new cancer cases...
By Trevan Locke, PhD Thanks to a wave of newly approved therapies in the past two decades, survival rates...
Multiple myeloma arises in immune cells called plasma cells. It is one of the most commonly diagnosed hematological malignancies...
Myeloma is the third most common blood cancer in the United States, arising in the plasma cells of the...
On Monday, the U.S. Food and Drug Administration (FDA) rounded out an exciting month for the multiple myeloma community...
The flurry of decisions from the U.S. Food and Drug Administration (FDA) on investigational anticancer therapeutics continued last week...
Just days before the start of multiple myeloma awareness month, which began Sunday, March 1, the U.S. Food and...